Published On: Wed, Oct 19th, 2016

La Jolla Pharmaceutical Company (LJPC) Updated Broker Ratings


A number of investment brokers have recently updated their price targets on shares of La Jolla Pharmaceutical Company (LJPC).

Most recent broker ratings

06/22/2016 – SunTrust began new coverage on La Jolla Pharmaceutical Company giving the company a “buy” rating. They now have a USD 30 price target on the stock.

05/24/2016 – Lake Street began new coverage on La Jolla Pharmaceutical Company giving the company a “buy” rating. They now have a USD 25 price target on the stock.

02/09/2016 – Cowen began new coverage on La Jolla Pharmaceutical Company giving the company a “outperform” rating. They now have a USD 40 price target on the stock.

01/15/2016 – Noble Financial began new coverage on La Jolla Pharmaceutical Company giving the company a “buy” rating. They now have a USD 37 price target on the stock.

09/08/2015 – La Jolla Pharmaceutical Company had its “buy” rating reiterated by analysts at Chardan Capital. They now have a USD 80 price target on the stock.

05/13/2015 – La Jolla Pharmaceutical Company was upgraded to “hold” by analysts at Zacks.

05/11/2015 – La Jolla Pharmaceutical Company had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 20 price target on the stock.

04/21/2015 – Oppenheimer began new coverage on La Jolla Pharmaceutical Company giving the company a “outperform” rating. They now have a USD 43 price target on the stock.

04/07/2015 – La Jolla Pharmaceutical Company had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 25 price target on the stock.

10/24/2014 – La Jolla Pharmaceutical Company had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 45 price target on the stock.

The share price of La Jolla Pharmaceutical Company (LJPC) was up +0.54% during the last day of trading, with a day high of 19.01. 105571 shares were traded during the last session.

The stock’s 50 day moving average is 21.63 and its 200 day moving average is 18.64. The stock’s market capitalization is 337.70M. La Jolla Pharmaceutical Company has a 52-week low of 12.68 and a 52-week high of 35.95.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. Its product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. The Company is developing LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). The Company is developing LJPC-401 for the treatment of iron overload, which occurs as a result of diseases, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. It is developing LJPC-30Sa and LJPC-30Sb not only for the treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.